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Background: Atrial fibrillation (AFib) exists more frequently in patients with aortic stenosis (AS) than in patients
without, and AFib may be a sign of progressive deterioration of AS. Echocardiographic assessment of AS in sinus
rhythm is well documented, however, little is known about AFib in AS since such patients often are excluded from
clinical echocardiographic trials.
Aim: The purpose of this study was to assess the prognostic importance of AFib in AS.
Methods: The study was designed as a single-center case-control study. Patients with AS and AFib were enrolled
as cases (n = 103) and subsequently matched to controls (103 patients with AS but sinus rhythm). Cases and
controls were matched according to age, gender and severity of AS. Primary outcome was all cause mortality and
follow-up was 100% complete.
Results: Compared to controls the group with AFib had lower mean ejection fraction (42% vs. 49%; p < 0.001) and
stroke volume (47 mL vs. 55 mL; p = 0.004), but higher heart rate (81 bpm vs. 68 bpm; p < 0.001) and no significant
difference with regard to cardiac output (3.8 L vs. 4.0 L; p = 0.29). Accordingly, aortic jet velocity and gradients were
significantly lower in AFib compared to controls but there were no differences (p = 0.38) in aortic valve area
calculated by the continuity equation. During a median follow-up of 2.3 years (IQR: 1.2-3.6), 70 (34%) patients with
AS died: 42 patients with AFib and 28 patients with sinus rhythm (p < 0.02). After adjusting for echocardiographic
significant differences, AFib remained an independent predictor of mortality (HR 2.72 (95% CI: 1.12–6.61), p < 0.03).
There was no significant interaction (p = 0.62) between AFib and AS on the risk of mortality, indicating that AFib
predicted bad outcome regardless of the severity of AS.
Conclusions: AFib is an independent risk factor in patients with AS and the prognostic impact of AFib seems to be
the same despite the severity of AS.
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Aortic stenosis (AS) and atrial fibrillation (AFib) are two
conditions associated with high cardiovascular morbidity
and mortality [1-5]. The incidences increase with age
and as populations are ageing; both conditions are likely
to become a greater public burden [1,2,6].
The left ventricular (LV) response to AS is hyper-
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distribution, and reproduction in any mediumpressure and left atrial dilatation [1,5,7,8]. Left atrial dila-
tation increases the risk of AFib [4,5] and the combin-
ation of impaired atrial contraction, LV hypertrophy and
elevated LV filling pressure leads to diastolic and systolic
dysfunction causing more symptoms and clinical deteri-
oration [5,9]. There is a moderate overrepresentation of
AFib in AS, indicating that AFib is related to the severity
of AS [10] and possibly a sign of progressive deterior-
ation of AS. Pre-operative AFib is a predictor of post-
operative mortality and/or morbidity after aortic valve
replacement [11-14], and longstanding AFib in AS is
associated with increased risk of heart failure [10].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(SR) is well documented; however, echocardiographic
documentation of patients with AS and AFib is limited.
The beat-to-beat variation in AFib complicates echocar-
diographic assessment and patients with AFib are often
excluded from echocardiographic clinical trials. Clinical
echocardiographic trials addressing the combination of
AFib in AS are therefore needed.
We hypothesized that AFib is an adverse sign in AS in
general, leading to impaired cardiac function as assessed




The study was designed as a single-center case-control
study. Since 2005, all echocardiographic examinations at
Gentofte University Hospital have been digitally stored.
Patient data were collected from patient files and a local
hospital database for patients undergoing invasive car-
diac treatment or thoracic surgery.
Study population
Echocardiographic examinations of hospitalized patients
and out-patients at the Department of Cardiology,
Gentofte University Hospital, are performed by dedicated
sonographers according to a standardized protocol. All
exams are digitally stored in a database on a central
server. From this database all patients with AS and a
standard transthoracic echocardiographic examination
(n = 1,002) were selected. We found 117 patients diag-
nosed with both AS and AFib. 6 patients were excluded
because of poor image quality and 8 patients were diag-
nosed with paroxysmal AFib, but were in SR at the time
of echocardiography. The remaining 103 patients were
included in the study as cases (AS and AFib at the time
of echocardiography). After echo analysis of the 103
cases; 103 matching controls were found in the database.
Matching was made by age, gender, and severity of AS.
Some cases had >1 matching control in the database, in
these circumstances the controls were randomly selected
by lot.
Outcome
Outcome was all cause mortality. Participants were fol-
lowed until May 2011 or time of death, using the unique
personal identification number in the Central Office of
Civil Registration. Follow-up was 100% complete.
Patient data
Height, weight, medications, symptoms, co-morbidities
and cardiovascular risk factors were collected from a
local database at the Department of Cardiology and
the Department of Cardiothoracic Surgery, GentofteUniversity Hospital and from patient files. Body Surface
Area (BSA) was calculated using the DuBois formula:
BSA m2
  ¼ 0:20247Weight kgð Þ0:425
Echocardiographic analyses
Echocardiography was performed using Vivid 7 or Vivid
E9 (General Electric Healthcare, Horten, Norway) be-
tween December 2005 and December 2010 and analyzed
de novo by one person blinded to clinical information
using EchoPAC PC version 108.1.12 (General Electric
Healthcare, Horten, Norway). Most patients had more
than one examination in the database. To ensure early
inclusion and long follow-up the first digitally stored
examination was included. Severity of AS were graded in
mild, moderate and severe AS in agreement with current
guidelines [15]. Maximum pressure gradient was calcu-
lated from the maximum jet velocity across the aortic
valve and the left ventricular outflow tract (LVOT) using
the modified Bernoulli equation. LVOT diameter was
measured in mid-systole from the parasternal long-axis
view. Aortic Valve Area (AVA) was calculated by the con-
tinuity equation [15]. Mild degrees of mitral and aortic
regurgitation were evaluated using multiple views of color
flow imaging measuring the origin, direction and size of
the regurgitation jet. In suspicion of moderate or severe
regurgitation; vena contracta width, pressure half-time
(for aortic regurgitation) and if possible also regurgitant
volume was calculated [16,17].
Heart rate was averaged from 15 heart cycles in AFib
and 7 heart cycles in SR. To optimize echocardiographic
assessment of LV function and to reduce the influence
of beat-to-beat variation in AFib, means from two or
more heart cycles were used.
LV dimensions were estimated from the parasternal
long-axis view. LV mass was calculated using the
Devereux formula [18] and indexed to BSA. The LV end-
diastolic and end-systolic volumes and left ventricular
ejection fraction (LVEF) were estimated using Simpson’s
method in the apical four- and two-chamber view. End-
systolic left atrial volume was calculated using the area-
length method in the apical four- and two-chamber view.
Trans-mitral Early inflow (E) and Deceleration Time
were obtained from pulsed wave Doppler in the apical
four-chamber view. Pulmonary valve jet velocity was
obtained using continuous wave Doppler from the para-
sternal short-axis view. Tricuspid valve regurgitation vel-
ocity was obtained using continuous wave Doppler from
a modified apical four-chamber-view optimized for the
right-sided chambers. Peak gradients for pulmonary valve
and tricuspid valve regurgitation were calculated using
the Bernoulli equation [15]. Right atrial pressure was
estimated as normal (3 mmHg), intermediate (8 mmHg)
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of the inferior vena cava in the subxiphoidal view [19].
Systolic pulmonary artery pressure was determined by
adding the tricuspid valve regurgitation gradient and the
estimated right atrial pressure. Peak early diastolic longi-
tudinal mitral annular velocity (e’) was measured using
pulsed wave tissue Doppler in the lateral mitral annulus
in the apical four-chamber view. Iso-volumetric relax-
ation time were calculated using tissue Doppler M-mode
of the anterior mitral leaflet in the apical four-chamber-
view [20].
Operative risk calculation
The operative mortality risk of aortic valve replace-
ment was evaluated for each patient using European
System for Cardiac Operative Risk Evaluation (Euro-
SCORE). Variable definitions were in accordance to
the definitions listed on the EuroSCORE website
(http://www.euroscore.org/). To minimize the influ-
ence of low LVEF, EuroSCORE was also calculated
without the influence of “LV dysfunction”.
Statistical analyses
Continuous variables are presented as median and inter-
quartile range, and categorical variables as number and
percentages. Fisher’s exact test was used to compare cat-
egorical data and since many of the continuous variables
were not normally distributed, Wilcoxon signed-rank test
was used to compare continuous variables. Cumulative
survival curves were established by the Kaplan-Meier
method, and the curves were compared using the log-
rank test. Cox proportional hazards regression models
were used to examine the associations of AFib and base-
line variables with the risk of mortality. All tests of sig-
nificance were two-tailed. Statistical significance was
defined as p < 0.05. SAS software (SAS System for
Windows, release 9.2, SAS Institute Inc., Cary, NC, USA)
was used to perform all statistical analyses.
Results
Study population
A total of 206 patients with AS (103 cases with AFib and
103 matched controls with SR at baseline) were included
in the study. Population characteristics are summarized
in Table 1. Five patients in the control group received
Warfarin: indications were severe atherosclerosis, pul-
monary emboli, apical aneurism with thrombus and con-
genital anti-thrombin deficiency. There was a trend for
significant difference between the two groups regarding
the presence symptoms (p = 0.08); the control group
reported more frequently angina whereas dyspnea were
more frequent in the case group (Table 1). EuroSCORE
were lower in the case group, however, this difference
was all explained by the difference in LVEF between thegroups: when removing the influence of LV dysfunction
from EuroSCORE, there were no significant differences
between cases and controls (Table 1). There was a differ-
ence in surgery between the two groups; 59 controls and
45 cases underwent aortic valve replacement (p = 0.05).
Echocardiography
Results from the echocardiographic examinations are
summarized in Table 2. The case group had a lower
median LVEF and stroke volume, but there was no dif-
ference in cardiac output and cardiac index (Table 2).
Aortic velocities and gradients were lower in the case
group, but when AVA was calculated by the continuity
equation no significant differences were found (Table 2).
Cases and controls were matched on the severity of AS
(p = 1.00). No differences with regard to aortic regurgita-
tion (p = 0.69) were found; by contrast the severity of
mitral regurgitation was distributed differently between
the two groups (p= 0.002), cases had a more severe degree
of mitral regurgitation than the controls: None (15% vs.
6%), trivial (46% vs. 28%), mild (36 % vs. 59%), moderate
(2% vs. 6%), and severe (1% vs. 1%) mitral regurgitation.
Mortality
During a median follow-up of 2.3 years (IQR: 1.2–3.6),
70 (34%) patients died: 42 patients with AS and AFib
and 28 patients with AS and SR (p < 0.02). Patients with
AS and AFib had a significantly higher risk of death
compared to controls (Figure 1).
Severe AS was present in nearly 50% of the patients at
baseline, but the mortality risk remained significantly
higher in cases after adjustment for severe AS (hazard
ratio 1.74, 95% confidence interval: 1.07–2.83; p < 0.03).
No significant interaction was found between severity of
AS and AFib on the risk of mortality (p = 0.62).
Significant differences in the echocardiographic para-
meters were found between the case and control group
(Table 2) however AFib remained significantly associated
with mortality after adjustments for conventional echo-
cardiographic parameters of forward and backward fail-
ure (Table 3). Similarly, AFib remained significantly
associated with mortality (hazard ratio 1.78, 95% confi-
dence interval: 1.10–2.91; p < 0.02) after adjustment for
mitral regurgitation (p = 0.80).
Discussion
Atrial fibrillation predicts mortality in aortic stenosis
In this study we analyzed echocardiographic examina-
tions from 103 patients with AS and AFib and compared
them with 103 controls (with AS but and SR) matched
on age, gender and severity of AS. We found that patients
with coexistence of AS and AFib had significantly higher
risk of death compared to controls (Figure 1). This differ-
ence remained after adjustment for LVEF, left atrial
Table 1 Population characteristics at baseline
CONTROLS CASES P-value
Aortic stenosis & sinus
rhythm
Aortic stenosis & atrial
fibrillation
Age , years 78 (73–84) 78 (73–84) 0.96
Male gender, n (%) 70 (68) 70 (68) 1.00
Body Mass Index, kg/m2 25.7 (22.3–28.1) 25.5 (22.3–27.5) 0.65
Body Surface Area, m2 1.88 (1.76–2.06) 1.89 (1.75–2.06) 0.90
Heart rate (bpm) 68 (63–77) 81 (73–96) <0.001
Cardiovascular risk factors and co-morbidities
Hypertension, n (%) 57 (57) 55 (55) 0.78
Smoking (previous or current), n (%) 57 (64) 65 (72) 0.24
Peripheral vascular disease, n (%) 5 (5) 13 (16) 0.02
Diabetes (Type I or II), n (%) 22 (21) 25 (24) 0.62
Hypercholesterolemia, n (%) 47 (49) 46 (46) 0.63
Stroke, n (%) 15 (15) 14 (15) 0.94
Ischaemic heart disease, n (%) 27 (26) 34 (33) 0.29
Familiar disposition, n (%) 14 (18) 16 (22) 0.49
Chronic lung disease, n (%) 22 (21) 17 (17) 0.38
Medication
β-blockers, n (%) 37 (41) 58 (58) 0.02
Calcium-antagonists, n (%) 21 (23) 22 (22) 0.83
ACE-inhibitors and/or Angiotensin-II-receptor-antagonists, n (%) 42 (47) 38 (38) 0.23
Diuretics (any kind), n (%) 46 (51) 65 (65) 0.05
Loop-diuretics, n (%) 19 (21) 51 (51) <0.001
Thiazides, n (%) 27 (30) 15 (15) 0.013
Potassium-sparing diuretics, n (%) 6 (7) 9 (9) 0.55
Insuline, n (%) 11 (12) 3 (3) 0.02
Oral antidiabetics, n (%) 10 (11) 14 (14) 0.55
Statins, n (%) 51 (57) 48 (48) 0.23
Aspirin, n (%) 57 (63) 50 (50) 0.06
Inhaled Medications (glucocorticoids/anticholinergics/β2-agonists), n (%) 9 (10) 11 (11) 0.82
Warfarin, n (%) 5 (6) 59 (59) <0.001
Digoxin, n (%) 0 45 (45) <0.001
Amiodarone, n (%) 0 2 (2) 0.18
Operative risk calculations
Additive EuroSCORE 8 (7–10) 9 (7–10) 0.05
Additive EuroSCORE without LV dysfunction 7 (6–9) 7 (6–9) 0.39
Symptoms
Symptoms (angina pectoris, dyspnea, dizziness, syncope), n (%) 75 (77) 87 (86) 0.08
Angina pectoris, n (%) 43 (43) 28 (28) 0.02
Dyspnea, n (%) 59 (63) 80 (80) 0.008
Dizziness, n (%) 12 (13) 17 (17) 0.41
Syncope, n (%) 5 (5) 9 (9) 0.31
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right atrial pressure, estimated systolic pulmonary artery
pressure and E/e’ (Table 3). A few studies have described
an increased mortality in patients with AS and AFib
undergoing surgical intervention [11-14], and one studybased on a selected population have found an increased
risk of heart failure and non-hemorragic stroke in AS
and AFib. The same study also found that new-onset
AFib was associated with cardiac decompensation [10].
More studies describing mortality and morbidity before
Table 2 Echocardiograpic findings
CONTROLS CASES P-value
Aortic stenosis & sinus rhythm Aortic stenosis & atrialfibrillation
Median (IQR) Median (IQR)
Left ventricle
LVEF (%) 49 (41–56) 42 (33–51) <0.001
LVEDV (ml) 112 (91–144) 119 (87–148) 0.86
LVESV (ml) 58 (40–75) 67 (43–91) 0.15
Stroke volume (ml) 55 (44–68) 47 (40–57) 0.004
Cardiac output (l) 3.8 (3.0–4.7) 4.0 (3.3–4.8) 0.29
Cardiac index (l/m2) 2.1 (1.6–2.5) 2.1 (1.7–2.5) 0.63
LVM (g) 159 (125–208) 172 (133–228) 0.08
LVMI (g/m2) 87 (71–109) 94 (77–119) 0.17
Left atrial dimensions and volumes
LAV (ml) 82 (68–101) 92 (80–126) 0.006
LAV index (ml/m2) 46 (38–54) 48 (40–59) 0.11
LAD (cm) 3.9 (3.5–4.4) 4.7 (4.2–5.3) <0.001
Aortic valve velocities
AV jet velocity (m/s) 4.0 (3.3–4.6) 3.3 (2.8–4.1) 0.004
AV peak gradient (mmHg) 59 (39–79) 41 (28–64) <0.001
AV mean gradient (mmHg) 33 (21–43) 22 (15–38) 0.001
AVA (cm2) 0.88 (0.70–1.10) 0.85 (0.65–1.07) 0.38
Mitral inflow and diastolic measures
E (m/s) 0.77 (0.64–0.96) 1.04 (0.87–1.25) <0.001
DT (ms) 203 (148–267) 149 (123–189) <0.001
IVRT (ms) 98 (80–106) 77 (65–94) <0.001
e’ (lateral mitral annulus) (cm/s) 0.05 (0.04–0.07) 0.09 (0.08–0.12) <0.001
E/e’ 14.2 (10.9–19.0) 11.1 (8.07–15.7) <0.001
Pulmonary pressure measurements
TRmax (mmHg) 29 (24–35) 32 (26–39) 0.047
RA pressure (mmHg) 3 (3–3) 3 (3–8) 0.003
SPAP (mmHg) 32 (26–41) 36 (29–46) 0.028
AV Aortic valve, AVA Aortic valve area, DT = Mitral valve decerleration time, E = Mitral valve peak early diastolic inflow, e’ = Peak early diastolic velocity by pulsed
tissue doppler, IQR Interquartile range, IVRT Isovolumetric relaxation time, LAD Left atrial diameter, LAV Left atrial end-systolic volume, LVEDV Left ventricular
end-diastolic volume, LVEF Left ventricular ejection fraction, LVESV Left ventricular end-systolic volume, LVM Left ventricular mass, LVMI Left ventricular mass index,
n numbers, RA pressure Estimated right atrial pressure, SPAP Estimated systolic pulmonary artery pressure, TRmax Tricuspid valve regurgitant peak gradient.
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not an option) are needed. It seems as if this patient
group has become “scientifically neglected”. The prog-
nostic effect of AFib in heart failure is well documented
in clinical trials; in a meta-analysis AFib was associated
with total mortality in both randomized controlled trials
and observational studies [2] and another study found an
increased risk of death after adjusting for pre-existing
cardiovascular conditions related to AFib [4].
We found no significant interaction between severity
of AS and AFib on the risk of mortality, emphasizing
that the presence of AFib in AS worsen prognosis re-
gardless of the severity of the AS. Thus, AFib predicts
bad outcome not only in patients with severe AS butalso in patients with mild or moderate AS. The finding
of AFib being an independent risk factor in AS is an im-
portant original discovery since the diagnosis of AFib
from an electrocardiogram (ECG) is far more accessible
than evaluation of cardiac function by echocardiography
Additional file 1: Video 1 and Additional file 2: Video 2.
Echocardiographic differences between sinus rhythm and
atrial fibrillation
We observed lower LVEF and stroke volume in the
group with AFib; however, the group with AFib also had
higher heart rate but no differences in cardiac output or
cardiac index when compared to the group with SR.
Similarly, the group with AFib had lower aortic jet
Figure 1 Kaplan - Meier survival curves. Shown is the cumulative
survival in patients with aortic stenosis and atrial fibrillation (+AFib),
compared to patients with aortic stenosis in sinus rhythm (-AFib).
The curves are compared using the log-rank test.
Table 3 Atrial fibrillation as a predictor of mortality by
Cox proportional hazard regression models
Hazard ratio P-value
(95% CI)
Model 1.94 (1.19-3.15) P < 0.01
Model + LVEF 1.75 (1.05-2.92) P < 0.03
Model + LAV 1.84 (1.04-3.26) P < 0.04
Model + TRmax 2.06 (1.20-3.56) P < 0.01
Model + RA pressure 2.21 (1.19-4.12) P < 0.02
Model + SPAP 2.37 (1.24-4.52) P < 0.02
Model + E/e’ 2.80 (1.66-4.72) P < 0.001
Model + LVEF + LAV + TRmax + SPAP + E/e’ 2.72 (1.12-6.61) P < 0.03
Model = Adjusted for age, gender and aortic stenosis severity.
CI Confidence interval, LAV Left atrial end-systolic volume, LVEF Left ventricular
ejection fraction, RA pressure Estimated right atrial pressure, SPAP Estimated
systolic pulmonary artery pressure, TRmax Tricuspid valve regurgitant peak
gradient.
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velocities to the velocities in LVOT using the continuity
equation no differences were found with regard to AVA
(Table 2). Severity of AS is determined using the aortic
jet velocity, mean gradient and AVA [15] and since
trans-valvular velocities are lower in AFib, patients with
AFib might be graded with a less severe degree of AS.
There was no difference in AVA, indicating that vel-
ocities and gradients should be used in the continuity
equation for calculation of the AVA and not for grad-
ing of AS severity in AFib (Figures 2 and 3).
Diastolic measurements and interpretation of diastolic
dysfunction should always be used with careful attention
in atrial fibrillation. Absence of atrial contraction in
AFib makes it necessary to interpret diastolic filling from
parameters independent of atrial contraction; such as
E/e’, Iso-volumetric relaxation time and deceleration
time. However, those parameters will always be affected
in the presence of AFib. Loss of atrial contraction and
only one diastolic filling phase causes higher e’ and con-
sequently low E/e’. Both iso-volumetric relaxation time
and deceleration time are dependent of heart rate. High
heart rate causes short iso-volumetric relaxation time
and paradoxically short deceleration time [21,22].Echocardiographic difficulties in atrial fibrillation
Echocardiographic assessment of AS during AFib is diffi-
cult and requires reflection. Myocardial contractility
depends on the preceding (R-R1) and pre-preceding
(R-R2) R-R interval, which is constantly changing in AFib.
(R-R1)/(R-R2) = 1 should represent the average value of
contractility for all cardiac cycles in AFib and should
therefore be used [23]. In the clinical setting the two pre-
ceding R-R intervals should have identical R-R intervals.
We used means from as many cycles as possible, usually
2–7 cycles, and tried to use cycles where the precedingand pre-preceding cycles were visible, but this was un-
fortunately not always possible. In general short R-R
intervals cause poor relaxation and impaired diastolic
filling, whereas longer R-R intervals favors relaxation
and proper diastolic filling [5]. Preceding R-R intervals
between 875–935 ms should assure sufficient diastolic
filling. Dubery et al. tried to find the optimal number of
beats for Doppler measurements in AFib. They found
that a mean of 13 beats was required to achieve an esti-
mation of cardiac output with a variability of less than 2%
[24]. The Echocardiographic assessment of valve stenosis:
EAE/ASE recommendations for clinical practice suggests
measurement from a minimum of five cardiac cycles if
AFib in mitral stenosis and tricuspid stenosis [15].
We suggest that; for optimal echocardiographic assess-
ment in AFib, importance should be put on optimizing
the calculation of the AVA by the continuity equation.
One should, as always, pay attention to the technical
details for accurate Doppler jet velocity curves. When
interpreting Doppler jet velocities over valves; any devi-
ation from the parallel angle of the blood flow will result
in underestimation of the jet velocity and should be
avoided. When grading the severity, most importance
should be put on the AVA. Heart rate should be
60–70 bpm and R-R intervals used in measurement
should not differ from each other.
Timing of surgery in atrial fibrillation
Timing of surgery in AS should be based on both
clinical and echocardiographic assessment [25-27]. How-
ever, both clinical and echocardiographic assessment
might be complicated in AFib. The natural history of AS
is characterized by a phase with increased obstruction
and adaptive mechanisms in the ventricle called the
“latent” period. Once symptoms occur, the clinical out-
come is extremely poor, with two-year survival rates
Figure 2 Calculation of the Aortic Valve Area by the continuity equation, patient in atrial fibrillation. Aortic jet velocity, left ventricular
outflow velocity and diameter of the left ventricular outflow tract. Male patient aged 77 with severe aortic stenosis, matched to the patient in
Figure 3. Aortic valve area (0.80 cm2). Ejection fraction (31%). Cardiac Index (1.80 l/m2). Stroke volume (50 ml).
Burup Kristensen et al. Cardiovascular Ultrasound 2012, 10:38 Page 7 of 9
http://www.cardiovascularultrasound.com/content/10/1/38<50% [3,9,27,28]. Symptoms of AS might be dyspnea, an-
gina pectoris, dizziness or syncope, which correlates very
well to the symptoms of AFib and it might be difficult or
even impossible to assess the underlying real etiology of
symptoms [29]. Not surprisingly; AFib is associated with
missed diagnosis of severe AS, despite systolic murmur
and symptoms of angina pectoris [30]. Langanay et al.
found AFib to be predictive for an increased operative
risk and suggests early referral of patients for surgery,
before progression of disease and onset of cardiac dys-
function [14]. Most guidelines today recommend surgery
of symptomatic patients with severe AS, which compli-
cates decision making and threatens adequate treatment
for patient with AFib. There are a few circumstances
where also asymptomatic patients with AS are recom-
mended surgery. These are patients with severe or mod-
erate AS undergoing coronary artery bypass surgery or
surgery of the ascending aorta, severe AS and systolic LV
dysfunction with LVEF <50%, severe AS and abnormal
exercise testing (symptoms during exercise, fall in blood
pressure below baseline, complex ventricular arrhythmias),
moderate-to-severe and severe AS with rapid progressionFigure 3 Calculation of the Aortic Valve Area by the continuity equat
outflow velocity and diameter of the left ventricular outflow tract. Male pat
Figure 2. Aortic valve area (0.88 cm2). Ejection fraction (43%). Cardiac Indexof peak velocity, severe AS and excessive LV hypertrophy
not due to hypertension and low gradient (<40 mmHg)
AS and LV dysfunction with or without contractile
reserve. The decision to operate on asymptomatic patients
requires careful weighting of benefits against risks and
should only be performed in selected patients at low
operative risk [25,26]. The clinical setting contains
many dimensions and the etiologies of symptoms in our
population are most likely a combination of both AS and
AFib.
The combination of doubts regarding etiology of symp-
toms and echocardiographic difficulties in AFib might in-
crease the risk of surgical delay, with the risk that
patients develop high surgical risk, heart failure and
becomes in-operable with poor chance of survival. In our
study, aortic valve replacement was more frequent in the
control group, despite the fact that cases and controls
were matched according to age, sex and AS severity.
Withholding of aortic valve replacement may well be an
intermediate component cause of atrial fibrillation pre-
dicting mortality, which emphasizes the importance of
an aggressive approach towards surgery in patients withion, patient in sinus rhythm. Aortic jet velocity, left ventricular
ient aged 77 with severe aortic stenosis, matched to the patient in
(1.93 l/m2). Stroke volume (63 ml).
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found AFib to be a predictor of per-operative and post-
operative mortality in patients receiving AVR [11-14].
However, in an Italian multi-center study, AFib was not a
predictor of mortality after Transcatheter Aortic Valve
Implantation [31] and in a smaller study no difference in
prognosis between AFib and SR after TAVI was
observed, despite a higher surgical risk in the group with
AFib [32].
As incidences of both AFib and AS increases with age
and as the population is aging, more patients with both
conditions must be expected in the future; clinical trials
addressing the combination of AFib and AS and the
echocardiographic assessment are needed.Potential limitations
Our data was retrospectively collected from the echocar-
diography database, patient files, discharge letters and
the local database for patients undergoing cardiovascular
intervention or thoracic surgery. Some data were unfor-
tunately not accessible. There were 25 cardiovascular
deaths in the case-group and 15 cardiovascular deaths in
the control-group. Cause of death was unfortunately not
available for 12 patients and statistics regarding impact
on cardiovascular has therefore not been included in the
manuscript.
We did not distinguish between paroxysmal and per-
manent AFib, therefore some of the patients in the
case group might have had only a single episode of
AFib (during the echocardiographic examination).
There is also a risk that some of the patients in the
control group might have had unknown episodes of
paroxysmal AFib. However, this would only dilute the
effect of AFib.
The study was performed at a tertiary referral center.
Many patients were followed elsewhere and referred to
our department because of deterioration in clinical status
and/or evaluation for surgery. The population might not
be representative of the AS patient and there might be a
false shortening of follow-up time.
The study cohort is composed of exclusively Cauca-
sians, which may limit the generalizability of our find-
ings to other ethnic groups.Conclusion
AFib is an independent risk factor of mortality in
patients with AS and AFib predicts bad outcome in
patients with not only severe AS but also in mild or
moderate AS. At the clinical follow-up of the patient
with AS and AFib both conditions must be in mind
when evaluating symptoms and when quantifying the
severity of AS.Additional files
Additional file 1: Video 1. Atrial fibrillation. Parasternal long-axis view.
Case and control (77 year, male, severe aortic stenosis). The same patients
used as example in Figures 1 and 2. The patient with atrial fibrillation
died of heart failure after 2.2 years of follow up and the patient in sinus
rhythm was still alive after maximal follow up of 4.3 years.
Additional file 2: Video 2. Sinus rhythm. Parasternal long-axis view.
Case and control (77 year, male, severe aortic stenosis). The same patients
used as example in Figures 1 and 2. The patient with atrial fibrillation
died of heart failure after 2.2 years of follow up and the patient in sinus
rhythm was still alive after maximal follow up of 4.3 years.
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